Management of Transthyretin Amyloidosis

Published: Jul 22, 2022
Category
Guides & Guidelines
Key Information
Source
Swiss Medical Weekly
Year
2021
summary/abstract

These guidelines were written after an extensive literature search using MedLine publications from January 1980 to April 2021, under the terms "ATTR" AND "transthyretin" AND "amyloidosis". Only full articles in English were considered. Following the literature search and review, the steering committee developed a summary of relevant statements that were evaluated by all the participants. Consensus was established using online, single point-per-point voting, through a nominal group technique. Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity of ATTR amyloidosis and the variable presentation of symptoms at early disease stages, historically meant treatment delays. Diagnostic tools and therapy options of ATTR amyloidosis have markedly improved in recent years.

Abstract Source
https://smw.ch/article/doi/smw.2021.w30053
DOI
10.4414/smw.2021.w30053
Authors
Adalgisa Condoluci, Marie Théaudin, Rahel Schwotzer, et al.
Organisation
Oncology Institute of Southern Switzerland, Switzerland; University Hospital and University of Lausanne, Switzerland; University Hospital of Zurich, Switzerland; ETHZ, Switzerland; Cardiocentro Ticino, Switzerland; University of Bern, Switzerland; Università della Svizzera Italiana, Switzerland; Swiss Institute of Bioinformatics, Switzerland; University Hospital and University of Basel, Switzerland; Cantonal Hospital Graubünden, Switzerland; Cantonal Hospital Aarau, Switzerland; University Hospital and University of Geneva, Switzerland; Luzerner Kantonsspital, Switzerland; Università della Svizzera Italiana, Switzerland;